Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Want to cut your energy bills? Here’s how five experts are doing it 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
 Securities Case - EconoTimes)
NEW YORK, March 15, 2016 -- Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that April 4, 2016 is the last day to file lead plaintiff papers in the securities lawsuit against Insys Therapeutics, Inc. (Nasdaq:INSY). Insys investors are encouraged to contact Scott + Scott at (866) 326-5057 or email [email protected] to discuss their legal rights.
About the Lawsuit
The complaint alleges that, throughout the Class Period, Defendants issued materially false and misleading statements to investors and/or failed to disclose that: (1) Insys was engaged in the illegal and improper off-labeling marketing of Subsys; (2) certain Insys employees were complicit in an illegal kickback scheme operated for the purpose of increasing prescriptions of Subsys; and (3) as a result, Insys’ financial statements were materially false and misleading at all relevant times. After a series of news articles revealed that the Company had allegedly engaged in illegal and improper off-label marketing of Subsys, the Company’s shares fell dramatically in price, thereby injuring investors.
What you can do
If you purchased shares of Insys stock, you may have legal claims against the Company. If you want to discuss filing lead plaintiff papers, or have questions about your legal rights, please contact Geoffrey M. Johnson, Esq. or Joseph Halloran, Esq. by telephone at (866) 326-5057 or by email at [email protected] or [email protected].
About Scott + Scott, Attorneys at Law, LLP
Scott + Scott has significant experience prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm has offices in New York, London, Connecticut, California and Ohio. Please visit www.scott-scott.com for more information about the firm.
CONTACT: Scott + Scott, Attorneys at Law, LLP Geoffrey M. Johnson, Esq. Joseph Halloran, Esq. (216) 229-6088, toll-free (866) 326-5057 [email protected] [email protected]
